Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis

Inflammopharmacology

Volumn 21, Issue 3, 2013, Pages 253-259

  Sexton, Michelle ^a   Silvestroni, Aurelio ^b   Möller, Thomas ^b   Stella, Nephi ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cannabinoid; Cannabis; CCL2; Monocyte; Neuroinflammation; Transmigration

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHYTOCANNABINOID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; LONG TERM EXPOSURE; MALE; MIGRATION INHIBITION; MONOCYTE; NORMAL HUMAN; OUTCOME ASSESSMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; CANNABINOIDS; CANNABIS; CELL MOVEMENT; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; MONOCYTES; PILOT PROJECTS; POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; YOUNG ADULT;

EID: 84878980801     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-012-0133-9     Document Type: Article

References (45)

1. Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467-479
2. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84-87 (Pubitemid 30143137)
3. Castillo A, Tolon MR, Fernandez-Ruiz J, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 37:434-440
4. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E (2006) Cannabis use in patients with multiple sclerosis. Mult Scler 12:646-651 (Pubitemid 46940639)
5. Colton CA (2009) Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 4:399-418
6. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C (2010) The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224:93-100
7. Dawson J, Miltz W, Mir AK, Wiessner C (2003) Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 7:35-48 (Pubitemid 36204587)
8. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313-326
9. Doorenbos NJ (1971) Cultivation, extraction and analysis of Cannabis sativa L. Ann NY Acad Sci 191:3-14
10. Fetterman PS, Keith ES, Waller CW, Guerrero O, Doorenbos NJ, Quimby MW (1971) Mississippi-grown Cannabis sativa L: preliminary observation on chemical definition of phenotype and variations in tetrahydrocannabinol content versus age, sex, and plant part. J Pharm Sci 60:1246-1249
11. Franklin A, Stella N (2003) Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol- sensitive receptors. Eur J Pharmacol 474:195-198 (Pubitemid 37281448)
12. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H (2011) COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 71:2664-2674
13. Garden GA, Moller T (2006) Microglia biology in health and disease. J Neuroimmune Pharmacol 1:127-137 (Pubitemid 44257488)
14. Geissmann F, Jung S, Littman DR (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19:71-82 (Pubitemid 36859902)
15. Gonzalez-Navarro H, Vinue A, Vila-Caballer M, Fortuno A, Beloqui O, Zalba G, Burks D, Diez J, Andres V (2008) Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced IRS2-dependent signaling. Arterioscler Thromb Vasc Biol 28:2187-2194
16. Huang NL, Juang JM, Wang YH, Hsueh CH, Liang YJ, Lin JL, Tsai CT, Lai LP (2010) Rimonabant inhibits TNF-alpha-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway. Acta Pharmacol Sin 31:1447-1453
17. Izzo AA, Borrelli F, Capasso R, Dimarzo V, Mechoulam R (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515-527
18. Kishimoto S, Gokoh M, Oka S, Muramatsu M, Kajiwara T, Waku K, Sugiura T (2003) 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 278:24469-24475 (Pubitemid 37548598)
19. Klein TW, Cabral GA (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1:50-64 (Pubitemid 44257500)
20. Kulkarni O, Anders HJ (2008) CCL2/MCP1: a novel target in systemic lupus erythematosus and lupus nephritis. Z Rheumatol 67:220-224
21. Landucci E, Scartabelli T, Gerace E, Moroni F, Pellegrini-Giampietro DE (2011) CB1 receptors and post-ischemic brain damage: studies on the toxic and neuroprotective effects of cannabinoids in rat organotypic hippocampal slices. Neuropharmacology 60:674-682
22. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105:2699-2704 (Pubitemid 351520576)
23. Mach F, Steffens S (2008) The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol 20(Suppl 1):53-57 (Pubitemid 351552677)
24. Mahad DJ, Ransohoff RM (2003) The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15:23-32 (Pubitemid 36092176)
25. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13:492-497 (Pubitemid 46559830)
26. Miller AM, Stella N (2008) CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153:299-308
27. Miller AM, Stella N (2009) Microglial cell migration stimulated by ATP and C5a involve distinct molecular mechanisms: quantification of migration by a novel near-infrared method. Glia 57:875-883
28. Montecucco F, Burger F, Mach F, Steffens S (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294:H1145-H1155 (Pubitemid 351468709)
29. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF (2004) Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10:158-164 (Pubitemid 38499908)
30. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW (2002) Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 127:169-176 (Pubitemid 34603588)
31. Patinkin D, Milman G, Breuer A, Fride E, Mechoulam R (2008) Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol 595:1-6
32. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Dimarzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62:588-631
33. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
34. Prinz M, Priller J (2010) Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS. J Neuroimmunol 224:80-84
35. Raborn ES, Cabral GA (2010) Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor. J Pharmacol Exp Ther 333:319-327
36. Raborn ES, Marciano-Cabral F, Buckley NE, Martin BR, Cabral GA (2008) The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmune Pharmacol 3:117-129
37. Rossi S, Bernardi G, Centonze D (2010) The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 224:92-102
38. Roth MD, Baldwin GC, Tashkin DP (2002) Effects of delta-9- tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 121:229-239 (Pubitemid 36044554)
39. Sacerdote P, Massi P, Panerai AE, Parolaro D (2000) In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109:155-163
40. Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017-1030
41. van de Veerdonk FL, Netea MG (2010) Diversity: a hallmark of monocyte society. Immunity 33:289-291
42. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405 (Pubitemid 36258918)
43. Weiss JM, Downie SA, Lyman WD, Berman JW (1998) Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J Immunol 161:6896-6903 (Pubitemid 28562235)
44. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF (2009) Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 4:249-259
45. Zhang H, Hilton DA, Hanemann CO, Zajicek J (2011) Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D-evidence for altered expression in multiple sclerosis. Brain Pathol 21(5):544-557 Medicine